Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Akebia Therapeutics, Inc. (AKBA)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Cost of goods sold | 29.0% | 71.8% | 100.2% | 43.4% | 3.7% | 0.0% | 0.0% | |
| Gross profit | 71.0% | 28.2% | -0.2% | 56.6% | 96.3% | 100.0% | 100.0% | |
| Selling, general and administrative | 47.4% | 81.5% | 52.1% | 44.6% | 41.9% | 14.9% | 1446.9% | |
| Research and development | 44.1% | 69.2% | 74.0% | 96.4% | 140.1% | 127.4% | 7543.0% | |
| General and administrative | | | | | | | | |
| EBITDA | -8.7% | -106.4% | -77.0% | -73.9% | -84.6% | -42.0% | -8870.6% | |
| Depreciation | 0.6% | 0.9% | 0.7% | 0.7% | 0.4% | 0.3% | 19.3% | |
| EBITA | -9.3% | -107.3% | -77.7% | -74.6% | -85.0% | -42.3% | -8889.9% | |
| Amortization of intangibles | 12.3% | 16.9% | 10.7% | 10.9% | 0.7% | | | |
| EBIT | -21.6% | -124.2% | -88.4% | -85.5% | -85.8% | -42.3% | -8889.9% | |
| Pre-tax income | -31.6% | -132.4% | -129.9% | -85.5% | -82.8% | -40.7% | -8843.5% | |
| Income taxes | 0.0% | 0.0% | 0.0% | -2.0% | -13.6% | 0.0% | 0.0% | |
| Net income | -31.6% | -132.4% | -129.9% | -83.5% | -69.1% | -40.7% | -8843.5% | |
|